[Progress on medical treatment in the management of adenomyosis].

article OA: green CC0 ⤵ 4 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-07

Non-steroidal anti-inflammatory drugs, steroid hormones, GnRH agonists, and mifepristone manage adenomyosis symptoms, with drug choice depending on patient factors, though recurrence after withdrawal necessitates further study.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07

This paper reviews progress in medical treatment approaches for adenomyosis, surveying the types of pharmacologic options used and their roles in management. It synthesizes available evidence rather than reporting new experimental or clinical trial data, and the main limitation is that the paper’s conclusions depend on the scope and quality of previously published studies, which are summarized without presenting original endpoints. The review emphasizes how medical therapies have evolved for adenomyosis while acknowledging the need to interpret findings within the limitations of the existing literature. This paper is centrally about adenomyosis — it focuses on progress and developments in the medical treatment of adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Drug therapy plays an important role in alleviating the symptoms related to adenomyosis, improving the curative effect of surgery, delaying the progress of disease and promoting assisted reproduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice to control pain associated with adenomyosis, and are the only choice for patients with recent fertility requirements; steroid hormones, gonadotropin releasing hormone agonists and mifepristone can effectively relieve pain and control uterine bleeding, among which oral contraceptives, levonorgestrel-releasing intranterine system (Mirena) and dienogest are more effective and commonly used in clinic. Drug selection should be based on patient's age, symptoms, uterine size, fertility requirements and economical conditions. At present, there is no specific drug for adenomyosis, and symptoms are easy to recur after drug withdrawal, so the long-term drug use needs further study.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis Disease Management Female Humans Recurrence

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-17T06:13:18.893374+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:41.077124+00:00
License: CC0 · commercial use OK